ILCs by the expression of the transcription factor Eomesodermin (EOMES) and the cytolytic protein perforin (3, 4) .
In humans, two conventional NK cell subsets have been phenotypically defined based on CD56 and CD16 (FCRγIII) (5) . Since most research in human NK cell biology is based on peripheral blood, the herein predominant CD56
dim NK cell population is most extensively investigated. Based on circulating NK cells, CD56 bright and CD56 dim NK cells have usually been described as two functionally distinct subsets, cytokine producing and cytolytic, respectively. However, several observations challenge this strict difference, as that both subsets can be cytotoxic or produce cytokines, after appropriate in vitro stimulation. Upon target cell recognition, resting CD56 dim NK cells are highly cytotoxic, but can produce cytokines as well (6) (7) (8) . In contrast, CD56 bright NK cells require monokine activation (combinations of IL2/IL12/IL15/IL18) to acquire cytolytic activity and produce cytokines (6, (9) (10) (11) .
Although the CD56 dim NK cells predominate in blood, the CD56 bright NK cells are far more abundant in the human body due to their enrichment in lymphoid and non-lymphoid tissues (12) (13) (14) (15) (16) (17) (18) . In addition, CD56
bright NK cells comprise the major NK cell population in inflamed and cancer tissues (12, 14, 19) . Recently, tissue-resident CD56 bright NK cells were identified in liver, uterus, and lymphoid tissues, which points toward a tissuespecific function of CD56 bright NK cells (13, (15) (16) (17) (20) (21) (22) . In order to understand the NK cell diversity, it is essential to focus on how CD56 bright NK cells develop, distribute, and acquire or alter their phenotype and function specifically in a particular organ. The first four developmental stages (i.e., from hematopoietic stem cell to CD56 bright NK cell) were already reviewed extensively elsewhere and will not be discussed here (23, 24) . This review attempts to improve the understanding of human circulating and tissueresident CD56 bright NK cells by reappraising their distribution and developmental, functional, and phenotypical characteristics. In addition, we will address to the developmental relationship between CD56 bright (stage 4) and CD56 dim NK cells (stage 5) and speculate on the position of tissue-resident CD56 bright NK cells within the NK cell developmental pathway.
DiSTRiBUTiON, PHeNOTYPe AND FUNCTiON

CD56
bright NK cells are widely distributed throughout the human body. When compared with blood, CD56 bright NK cells are enriched in most human tissues. They represent the majority of NK cells in lymph nodes, tonsil, stomach, gut, liver, uterus, adrenal gland, and visceral adipose tissue (12) (13) (14) (15) (16) (17) (18) . Although CD56 bright NK cells seem to be outnumbered by CD56 dim NK cells in lung, kidney, mammillary tissue, bone marrow and spleen, this is probably a reflection of the high blood perfusion of these organs (12, 13, 18, 25) . Most knowledge on the phenotype and function of CD56 bright NK cells is derived from blood, but it is important to realize that unique subsets of tissue-resident CD56 bright NK cells have been described in lymphoid tissues, liver and uterus (13, 15, 22, 26) . Conceivably, more organs contain tissue-resident CD56 bright NK cell populations. To the best of our knowledge, no tissue-resident CD56 dim NK cells have been described to date. Although residency is often used as a term for organ-infiltrating NK cells, it is generally not discussed whether these NK cells are just trafficking through the organ, or truly tissue resident. In this review, we only apply the term "resident" if there is substantial evidence, which allows to distinguish the tissue-resident CD56 bright NK cells from circulating CD56 bright NK cells. The lack of CD56 expression on murine NK cells hampers the one to one comparison of CD56 bright NK cells to their murine counterpart. Due to limitations in obtaining human tissue samples, important findings in mice will be included in this review to cover the lack of human data.
Hallmarks of Tissue-Resident CD56 bright NK Cells
In order to be retained within the tissue, tissue-resident CD56 bright NK cells should possess characteristics, which prevent egress from the tissue. One of the mechanisms involved in residency is attributed to CD69, which is absent from blood-derived NK cells (13) . Originally, CD69 was identified as an early activation marker, but today CD69 is known to be associated with tissue residency by suppressing sphingosine-1-phospate receptor 1 (S1PR1) surface expression (27-29). Although initially identified in the context of T-and B-cell migration, S1PRs have also been proposed to mediate the egress of NK cells from tissues into blood and lymph in mice, driven by a S1P gradient (30) (31) (32) (33) (34) (35) . It has not been confirmed whether S1PRs are expressed as protein on the cell surface of human NK cell subsets in blood and tissues. At transcriptional level, however, both S1PR1 and S1PR5 are expressed in circulating human NK cells, with the latter being selective for CD56 dim NK cells (33, 36, 37) . In contrast to S1PR1, S1PR5 is not inhibited by CD69 (32) . Another potential mechanism for tissue homing and/or residency is the engagement of chemokine receptors. For instance, CXCR6 and CCR5 are both highly expressed on tissue-resident CD56 bright NK cells in lymphoid tissues and liver, but have a low expression on blood-derived CD56 bright NK cells, which instead express CCR7 (13, 15, 38) . A third mechanism of tissue retention is driven by the expression or absence of adhesion molecules. For instance, the integrin CD49a is highly expressed on uterine CD56 bright NK cells, but absent from blood NK cells (20) . Furthermore, tissueresident CD56 bright NK cells lack CD62L (L-selectin), which is like CCR7 involved in recruitment of circulating NK cells to lymphoid tissues via high endothelial venules (HEVs) (15, 17, 18, 38, 39) . Altogether, based on the expression of CD69, chemokine receptors, and adhesion molecules, tissue-resident CD56 bright NK cells can be distinguished from circulating CD56 bright NK cells. In addition to the phenotypical differences, tissue-resident CD56 bright NK cells are functionally different from their circulating counterparts as will be discussed in the next sections.
Lymphoid Tissues
Lymph Node
Lymph nodes contain 40% of the lymphocytes in the human body, of which 2-5% consist of NK cells ( Figure 1A) (12, 13, 18, 40) . bright NK cells is depicted as percentage of (A) total lymphocytes and (B) total NK cells within blood (13) , lymph node (13, 18, 25) , spleen (13, 18, 25) , bone marrow (13, 18, 25) , tonsil (18, 44) , liver (15, 45, 46) , endometrium (16, 20) , and decidua (20, 47 More than 75% of the NK cells in lymph nodes have a CD56 bright phenotype ( Figure 1B) (13, 18, 25) . Accumulating evidence suggests a model in which CD56 bright NK cells circulate from the blood to tissues, enter the lymphatic system, and eventually migrate back to the periphery via the efferent lymph (41, 42) . The mechanisms governing the migration to and infiltration of lymphoid tissues by CD56 bright NK cells are mainly deduced from chemokine receptor expression on circulating CD56 bright NK cells. As discussed earlier, circulating CD56 bright NK cells express CCR7 and CD62L (38, 39) . The chemokines engaging CCR7, CCL19, and CCL21 are both highly expressed in lymph nodes (12) . HEVs might not be the only route for circulating CD56 bright NK cells to enter the lymph node. NK cells in seroma fluid, which represents an accumulation of afferent lymph, resemble circulating CD56 bright NK cells regarding low expression of CCR5, killer-cell immunoglobulin-like receptor (KIR), and CD16 and high expression of CCR7 and CD62L (12, 43) . This suggests that circulating CD56
bright NK cells enter the lymph node both via HEVs and afferent lymph vessels.
Recently, we identified a major lymphoid tissue-resident NK cell subset in lymph node, spleen, and bone marrow based on co-expression of CD69 and CXCR6 ( Figure 2 ; Table 1 ) (13) . In the lymph node, lymphoid tissue NK (ltNK) cells account for 60% of all NK cells and cover the majority of the CD56 bright NK cell compartment ( Figure 1B) . LtNK cells display a slightly less intense CD56 and more intense NKp46 expression compared with circulating CD56 bright NK cells. In addition, the majority of ltNK cells is CD16 − , CD49a − , and CD27 + (13). Interestingly, most ltNK cells do not express DNAX accessory molecule 1 (DNAM1), an activating receptor which is uniformly expressed on circulating CD56 bright NK cells (13) . The remaining CD56 bright CD69 − NK cells closely resemble circulating CD56 bright NK cells, suggesting that these cells are blood-derived CD56 bright NK cells transiently circulating through the lymph node (13). Lymphoid tissue NK cells were tested in the functional assays classically used for NK cells. The ltNK cells were less potent IFN-γ producers compared with circulating CD56 bright NK cells nor did they lyse K562 target cells as efficient as CD56 dim NK cells (13) . However, the expression of EOMES and perforin distinguishes ltNK cells from the helper-ILC1 group (13) . These phenotypical and functional characteristics, combined with their specific location in lymphoid tissues where immune responses are initiated and shaped, point to a distinct yet undefined role of ltNK cells (50) .
Notably, without the use of tissue-resident markers, CD69 and CXCR6, ltNK cells could previously not be distinguished from circulating CD56 bright NK cells. Therefore, a re-examination of the function of CD56 bright NK cells in lymphoid tissue is necessary, in particular in the lymph node where a large population of ltNK cells co-exists next to the non-resident or circulating CD56 bright NK cells.
Spleen and Marrow
The spleen and bone marrow contain 14 and 10% of the total lymphocyte pool. NK cells constitute 5-20% and 4% of lymphocytes in spleen and marrow, respectively ( Figure 1A) (13, 18, 40, 43) . The CD56 bright and CD56 dim NK cells are equally distributed in the spleen, but 90% of CD56 bright NK cells consist of ltNK cells ( Figure 1B) (13, 25, 40) . Similar to the spleen, the bone marrow is enriched for CD56 bright NK cells, of which the majority consists of ltNK cells (13, 25) . The phenotype of ltNK cells in spleen and marrow resembles the ltNK cell population in lymph node. As mentioned before, the non-resident CD56 bright CD69
− and CD56 dim NK cells in marrow and spleen closely resemble the circulating CD56 bright and CD56 dim NK cells and are probably circulating NK cells contained in the tissue at time of isolation. Previously, the spleen has been reported to be enriched in CD27 + and NKp46 bright NK cells, which could be a reflection of ltNK cells. These findings further illustrate the importance of using tissue-resident markers to distinguish circulating from tissueresident CD56 bright NK cells (51, 52) . The manner in which NK cells enter the spleen differs from lymph node entrance, because the spleen does not contain afferent lymphatic vessels or HEVs (53) . In mice, NK cells enter the spleen via arterioles in the marginal zone, rather than via arterioles directly connected to the red pulp, where most NK cells reside (54) . Unfortunately, there is a lack of human studies focusing on how NK cells migrate to the spleen and bone marrow.
Tonsil
In tonsil, although the CD56 bright subset is predominant, only 0.4% of the total lymphocytes consist of NK cells ( Figure 1A ) (18) . Seventeen percent of the total NK cell population in the tonsil co-expresses CD69 and CXCR6 ( Figure 1B) (44) . In contrast to the ltNK cells in lymph node, marrow, and spleen, these tonsilresident NK cells also express NKp44, CD103, CD49a, Integrinβ7, and partly CD9 (Figure 2; Table 1 ) (44) . Of note, tonsil-resident NK cells should be distinguished from NKp44 + ILC3s, which 
Liver
Hepatic NK cells comprise 40% of all hepatic lymphocytes ( Figure 1A) (45) . Recently, a major liver-resident EOMES + CD56 bright NK cell population has been described, which comprises 45% of the hepatic NK cells and closely resembles ltNK cells phenotypically and functionally ( Figure 1B) (15, 45, 46) . Liver-resident CD56 bright NK cells are characterized by a simultaneous expression of CD69 and CXCR6 (46) . They have a high expression of CCR5 and NKp46, and low expression of DNAM1, as indirectly concluded from phenotypical analysis on total hepatic CD56 bright NK cells (Figure 2 ; Table 1 ) (15, 45 ). An independent report demonstrated the presence of a distinct minor liver-resident cell population characterized by CD49a expression (21) . Those CD56 bright CD49a + cells make up 2% of the total NK cell compartment in the liver but are not present in every individual (41% of donors) (13, 15, 21) . The expression of CXCR6 has not been described. However, these cells do not express EOMES, suggesting that they do not belong to the NK cell lineage (21) . Due to the low prevalence of this CD49a + EOMES − cell population, we can indirectly conclude that the major CD69 + CXCR6 + liver-resident NK cell population is negative for CD49a. The IFN-γ production of liver-resident CD56 bright NK cells after 4-h stimulation with IL12 and IL18 was lower compared with the non-resident hepatic NK cells (46) . Similar to ltNK cells, liver-resident CD56 bright NK cells express perforin and granzyme B at a low level, further supporting a non-cytotoxic function (46) . Several studies in mice demonstrated the existence of hapten and virus-specific hepatic NK cell memory, mediated by cells expressing CD49a and CXCR6 (21, 58, 59) . In contrast, splenic CXCR6 + NK cells, which potentially resemble the human ltNK cells, were not able to mediate a memory response (58) . Thus, although CXCR6 expression is not restricted to the liver, only hepatic NK cells were found to mediate a memory response in mice. Nevertheless, it would be interesting to further study the memory capacities of the highly prevalent CXCR6
+ liver-and lymphoid tissue-resident CD56 bright NK cells in humans.
Uterus
The uterine mucosa is populated by EOMES + CD56 bright NK cells (16, 17, 23) . In contrast to blood, there are hardly any CD56 dim NK cells detectable in endometrium (no pregnancy) and decidua (pregnancy) (16, 17, 20, 60) . Independent of the stage of the menstrual cycle, NK cells make up 30% of the endometrial lymphocytes ( Figure 1A) , although the absolute number of lymphocytes and NK cells increases robustly in the secretory stage (16) . During early pregnancy, however, more than 70% of the lymphocytes in the uterine decidua is represented by CD56 bright NK cells ( Figure 1A) (47) . Phenotypically, endometrial and decidual CD56 bright NK cells closely resemble each other, and will be further referred to as uterine CD56 bright NK cells. The CD56 expression of the uterine NK cells is even more intense than their circulating CD56 bright counterparts (Table 1 ) (17, 61) . All uterine NK cells display CD49a but not CCR5, discriminating them from the circulating, lymphoid tissue, and liver-resident NK cell populations (Figure 2) (16, 20) . DNAM1 has been reported to be absent on uterine NK cells, although a contradicting report on this observation exists (20, 48, 62) . Recently, it was shown that a fraction of uterine NK cells expresses the heterodimer CD103/ITGβ7, NKp44, as well as CD69 (20, 62) . Conversely, an earlier study reported that all decidual NK cells express CD69 (17) . Despite this discrepancy concerning the CD69 expression, both the CD56 bright CD103 − and CD56 bright CD103 + NK cells are likely to represent a tissue-resident CD56 bright NK cell population, as demonstrated by the expression of KIRs, CD9, and poor IFN-γ production and cytotoxicity (16, 17, 20, 49, 63, 64) . Moreover, transcriptome analysis of decidual NK cells and circulating NK cells highlighted the uniqueness of the uterine NK cells (17, 48) . To the best of our knowledge, the presence of chemokine receptors, such as CXCR6 and CCR5, has not been reported. Compared with circulating CD56 bright NK cells, decidual CD56 bright NK cells highly express the activating receptors NKG2C and NKG2E at RNA level; however, <30% is NKG2C + on protein level (17, 62, 65) . Initially, a suppressive function of decidual NK cells was thought to be essential to provide maternal-fetal tolerance (17, 64) . However, accumulating evidence points toward a more active role of decidual CD56 bright NK cells in regulating placentation, as reviewed elsewhere (66) . Decidual NK cells are considered to stimulate trophoblast invasion and spinal artery remodeling via the production of various chemokines and angiogenic factors (including angiopoietins and GM-CSF) (67) (68) (69) . Mice lacking decidual NK cells exhibit abnormalities in pregnancy, including abnormal vascular remodeling of decidual arteries (70) . Although the process of placentation in humans is different, specific combinations of fetal HLA-C alleles, presented by trophoblasts, and maternal KIR expression were shown to be associated with successful placentation (69, 71 dim NK cells, they have been assumed to have a shorter proliferative history (74) . A commonly used marker for immaturity, the tyrosine kinase c-kit (receptor for stem cell factor, CD117) is expressed on a fraction of CD56 bright NK cells, but is absent on CD56 dim NK cells (75, 76) . In addition, the recovery of CD56 bright NK cells in the first weeks after hematopoietic stem cell transplantation (HSCT) precedes the reconstitution of CD56 dim NK, a sequential occurrence potentially pointing toward a developmental relationship (74, 77) . Together, these findings resulted in the hypothesis that CD56 dim NK cells are derived from CD56 bright NK cells.
Differentiation from CD56 bright to CD56 dim NK Cells In Vitro
In efforts to provide evidence for this hypothesis, numerous studies aimed to recapitulate the differentiation from CD56 bright to CD56 dim NK cells in vitro. CD56 bright NK cells were shown to acquire a CD56 dim -like phenotype upon in vitro activation with IL-2, IL-15, and/or co-culture with T cells. This resulted in the upregulation of CD16 and KIRs and the downregulation of IL-7Rα (CD127), CD117, CXCR3, and CCR7 (10, 74) . However, the intensity of CD56 expression was not reduced on monokineactivated CD56 bright NK cells. The presence of fibroblast growth factor receptor 1 (FGFR1) was demonstrated to be critical for the in vitro differentiation of CD56 bright NK cells to cytotoxic CD56 dim NK cells in a contact-dependent manner (78) . FGFR1 is a ligand for CD56 and is constitutively expressed on fibroblasts (79, 80) . The high density of CD56 on CD56 bright NK cells may thus be of importance in the interaction with fibroblasts and differentiation toward CD56 dim NK cells.
Differentiation from CD56
bright to CD56 dim NK Cells In Vivo
The in vivo evaluation of the relationship between CD56 bright and CD56 dim NK cells is hampered by the lack of CD56 expression on murine NK cells. The vast majority of human CD56 bright NK cells displayed a reduction of CD56 expression intensity after infusion into immune-deficient mice (78) . Whether these in vivo differentiated CD56 dim NK cells were phenotypically and functionally similar to human blood-derived CD56 dim NK cells were not addressed in this study, leaving the possibility that the bright CD56 expression is not sustained in mice lacking human fibroblasts expressing FGFR1. An alternative for murine experiments can be provided by the study of rhesus macaques. (85, 86) . Notably, the expression of CD16, CD117, and CD27 on CD56 bright NK cells can also be modulated by cytokine-activation (10, 51, 74) . Because the post-HSCT setting presents a cytokine-rich environment, the "intermediate" CD16 
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